Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 9/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.35 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7114161 | 0.95 | CXCR4 (0.42) | CXCR4SMN1; SMN2SOS1SOS2MEN1 | |
| SCHEMBL6823025 | 0.84 | SOS1 (0.43) | CXCR4SMN1; SMN2SOS1SOS2ALDH1A1 | |
| SCHEMBL6961310 | 0.75 | SOS1 (0.45) | CXCR4SOS1SOS2ALDH1A1 | |
| SCHEMBL30660182 | 0.75 | SOS1 (0.41) | CXCR4SMN1; SMN2SOS1SOS2ALDH1A1 | |
| SCHEMBL20184166 | 0.75 | CXCR4 (0.36) | CXCR4SMN1; SMN2SOS1SOS2 | |
| SCHEMBL457018 | 0.72 | CXCR4 (0.36) | CXCR4SMN1; SMN2 | |
| SCHEMBL11478629 | 0.71 | — | — | |
| SCHEMBL16203347 | 0.69 | CXCR4 (0.42) | CXCR4SMN1; SMN2SOS1SOS2ALDH1A1 | |
| SCHEMBL3810559 | 0.69 | — | — | |
| Piperazine SCHEMBL7550059 | 0.69 | CXCR4 (0.48) | CXCR4SMN1; SMN2SOS1SOS2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140113969-A1 | Preventing And/Or Treating Cardiovascular Disease And/Or Associated Heart Failure | PHILERA NEW ZEALAND LIMITED (NZ) | 2014-04-24 | — | — | US | claimed |
| EP-1487431-A4 | PREVENTING AND/OR TREATING CARDIOVASCULAR DISEASE AND/OR ASSOCIATED HEART FAILURE | PROTEMIX CORP LTD (NZ) | 2006-10-25 | — | — | EP | claimed |
| US-6951890-B2 | Preventing and/or treating cardiovascular disease and/or associated heart failure | PROTEMIX CORPORATION LIMITED (NZ) | 2005-10-04 | — | — | US | claimed |
| US-20050131186-A1 | Living radical polymerization of halogen-containing and acrylic monomers and the formation of block copolymers therefrom | PENNSYLVANIA, UNIVERSITY OF | 2005-06-16 | — | — | US | claimed |
| EP-1487431-A1 | PREVENTING AND/OR TREATING CARDIOVASCULAR DISEASE AND/OR ASSOCIATED HEART FAILURE | Protemix Corporation Limited (NZ) | 2004-12-22 | — | — | EP | claimed |
| WO-2004017957-A1 | PREVENTING AND/OR TREATING CARDIOVASCULAR DISEASE AND/OR ASSOCIATED HEART FAILURE | PROTEMIX CORPORATION LIMITED (NZ) | 2004-03-04 | — | — | WO | claimed |
| US-20030203973-A1 | Preventing and/or treating cardiovascular disease and/or associated heart failure | PHILERA NEW ZEALAND LIMITED (NZ) | 2003-10-30 | — | — | US | claimed |
| WO-2003077901-A1 | PREVENTING AND/OR TREATING CARDIOVASCULAR DISEASE AND/OR ASSOCIATED HEART FAILURE | PROTEMIX CORPORATION LIMITED (NZ) | 2003-09-25 | — | — | WO | claimed |
| WO-2003075910-A1 | PREVENTING AND/OR TREATING VASCULAR DISEASE, CARDIOMYOPATHY AND/OR ASSOCIATED HEART FAILURE | PROTEMIX CORPORATION LIMITED (NZ) | 2003-09-18 | — | — | WO | claimed |
| CN-114867474-A | Combination therapy for central nervous system disorders | 菲勒拉新西兰有限责任公司 | 2022-08-05 | — | — | CN | disclosed |
| EP-3982943-A1 | COMBINATION TREATMENTS FOR CENTRAL NERVOUS SYSTEM DISORDERS | Philera New Zealand Ltd. (NZ) | 2022-04-20 | — | — | EP | disclosed |
| WO-2020257279-A1 | COMBINATION TREATMENTS FOR CENTRAL NERVOUS SYSTEM DISORDERS | PHILERA NEW ZEALAND LTD. (NZ) | 2020-12-24 | — | — | WO | disclosed |
| US-20140113969-A1 | Preventing And/Or Treating Cardiovascular Disease And/Or Associated Heart Failure | PHILERA NEW ZEALAND LIMITED (NZ) | 2014-04-24 | — | — | US | disclosed |
| US-8563538-B2 | Preventing and/or treating cardiovascular disease and/or associated heart failure | PHILERA NEW ZEALAND LIMITED (NZ) | 2013-10-22 | — | — | US | disclosed |
| US-6951890-B2 | Preventing and/or treating cardiovascular disease and/or associated heart failure | PROTEMIX CORPORATION LIMITED (NZ) | 2005-10-04 | — | — | US | disclosed |
| EP-1487431-A1 | PREVENTING AND/OR TREATING CARDIOVASCULAR DISEASE AND/OR ASSOCIATED HEART FAILURE | Protemix Corporation Limited (NZ) | 2004-12-22 | — | — | EP | disclosed |
| WO-2004017957-A1 | PREVENTING AND/OR TREATING CARDIOVASCULAR DISEASE AND/OR ASSOCIATED HEART FAILURE | PROTEMIX CORPORATION LIMITED (NZ) | 2004-03-04 | — | — | WO | disclosed |
| US-20030203973-A1 | Preventing and/or treating cardiovascular disease and/or associated heart failure | PHILERA NEW ZEALAND LIMITED (NZ) | 2003-10-30 | — | — | US | disclosed |
| WO-2003077901-A1 | PREVENTING AND/OR TREATING CARDIOVASCULAR DISEASE AND/OR ASSOCIATED HEART FAILURE | PROTEMIX CORPORATION LIMITED (NZ) | 2003-09-25 | — | — | WO | disclosed |
| WO-2003075910-A1 | PREVENTING AND/OR TREATING VASCULAR DISEASE, CARDIOMYOPATHY AND/OR ASSOCIATED HEART FAILURE | PROTEMIX CORPORATION LIMITED (NZ) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203973-A1 | Preventing and/or treating cardiovascular disease and/or associated heart failure | TNNI3, FABP3, TNNT2 | CXCR4 1025/4885SMN1; SMN2 583/4885SOS1 4561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.